ClinicalTrials.gg
CompletedNCT04660344IMvigor011Updated Nov 6, 2026Results posted

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

A Phase 3 interventional study of Atezolizumab and Placebo in Muscle-invasive Bladder Cancer, sponsored by Hoffmann-La Roche. Completed at 140 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 4 judgments

Updated Nov 6, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
761
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing atezolizumab in Urinary Bladder Neoplasms — 1 open to participants now, 11 under way, 2 of them phase 3. atezolizumab · Urinary Bladder Neoplasms.

Enrollment
3rd of 21
761 · median 96
Started
2021
the only one that year
Phase 3
6 of 21
none open now
Registered
19th of 21
by date
Lead sponsor
6 of 21
Hoffmann-La Roche

Among the 21 studies testing atezolizumab in Urinary Bladder Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 6 in phase 3, and was the 19th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

1 of the 21 studies testing atezolizumab in Urinary Bladder Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atezolizumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.

03

Conditions studied

  • Muscle-invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for the Surveillance Phase:

  • confirmed MIUC (also termed transitional cell carcinoma [TCC]) of the bladder
  • Tumor, nodes, and (TNM) classification (based on American Joint Committee on Cancer [AJCC] Cancer Staging Manual, 8th Edition; Amin et al. 2016) at pathological examination of surgical resection specimen as follows: For participants treated with prior chemotherapy (NAC): tumor stage of ypT2-4a or ypN+ and M0. For participants who have not received prior NAC: tumor stage of pT2-4a or pN+ and M0
  • Surgical resection of MIUC of the bladder
  • Participants who have not received prior platinum-based NAC must be ineligible for cisplatin-based adjuvant chemotherapy, have refused it, or will not receive it based on physician's decision
  • ctDNA assay developed based on tumor tissue specimen and matched normal DNA from blood
  • Tumor programmed death ligand () expression per immunohistochemistry (IHC) that is evaluable by central testing of a representative tumor tissue specimen
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest no more than 4 weeks prior to enrollment
  • Full recovery from cystectomy and enrollment within 24 weeks following cystectomy. Minimum of 6 weeks must have elapsed from surgery

Additional Inclusion Criteria for the Treatment Phase:

  • Blood for plasma ctDNA sample evaluated to be ctDNA positive, defined as the presence of two or more mutations out of the 16 mutations identified based on participant' whole exome sequencing (WES) evaluable (ctDNA assay designability) report
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline CT or MRI scan of the pelvis, abdomen, and chest no more than 28 days prior to randomization, as assessed by the investigator and Independent Review Facility
  • (ECOG) performance status of ≤ 2
  • ≥12 weeks
  • Adequate hematologic and end-organ function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use and agreement to refrain from donating eggs

Exclusion Criteria:

General Medical Exclusion Criteria for the Surveillance Phase:

  • Known PD-L1 IHC result for adjuvant therapy. The decision for the adjuvant therapy should not be based on the PD-L1 IHC result
  • Pregnancy or breastfeeding
  • Positive test for (HIV), with the following exception: Participants with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy, have a cluster of differentiation 4 (CD4) count ≥ 200 per microliter (/µL), and have an undetectable viral load
  • Participants with active virus (HBV) or virus (HCV). Participants with past HBV infection or resolved HBV infection are eligible. A negative HBV deoxyribonucleic acid (DNA) test must be obtained in these participants prior to enrollment. Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
  • Active tuberculosis (TB) confirmed by a test performed within 3 months prior to treatment initiation
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of disease. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. Participants with controlled type I diabetes mellitus (T1DM) on a stable dose of insulin regimen may be eligible for this study
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Significant cardiovascular disease, such as cardiac disease (Class II or greater), myocardial infarction (MI) within the previous 3 months, unstable arrhythmias, or unstable angina

Cancer-Specific Exclusion Criteria for the Surveillance Phase:

  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to study enrollment
  • Adjuvant chemotherapy or radiation therapy for UC following cystectomy
  • Treatment with any other agent or participation in another clinical trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is longer, prior to enrollment
  • other than UC within 5 years prior to study enrollment

Additional Exclusion Criteria for the Treatment Phase:

  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to randomization to the treatment phase. Hormone-replacement therapy or oral contraceptives are allowed
  • Adjuvant chemotherapy or radiation therapy for UC following cystectomy
  • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization to the treatment phase
  • Positive test for HIV, with the following exception: Participants with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy, have a ≥200/μL, and have an undetectable viral load
  • Participants with active HBV or HCV
  • Active tuberculosis confirmed by a test performed within 3 months prior to treatment initiation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
761 participants (actual)

Study arms

  • Experimental
    Arm A: Atezolizumab

    Atezolizumab will be administered intravenously (IV) at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.

    Drug: Atezolizumab · Device: Signatera

  • Placebo comparator
    Arm B: Placebo

    Placebo will be administered IV on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor. Following the primary analysis, participants randomized to the comparator arm might discontinue placebo and may receive treatment outside the study at the investigator's discretion.

    Other: Placebo · Device: Signatera

  • Experimental
    Arm C: Surveillance Follow-Up

    Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.

    Device: Signatera

Interventions

  • ctDNA positive participants will receive 1680 mg IV, every 4 weeks (Q4W) on Day 1 of each 28-day cycle.

    Also known as: Tecentriq

  • OtherPlacebo

    ctDNA positive participants will receive placebo IV, Q4W on Day 1 of each 28-day cycle

  • DeviceSignatera

    Signatera will be used to evaluate whether ctDNA is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.

06

What researchers measure

Primary outcomes

  1. INV-assessed Disease-free Survival (DFS)

    INV-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an INV-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. Kaplan-Meier (KM) methodology was used to estimate the median DFS.

    Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause. Data for participants who did not die at the time of analysis were censored at the date last known to be alive. Data for participants who did not have post-baseline information were censored at the date of randomization. KM methodology was used to estimate the median OS.

    Time frame: From randomization to death from any cause (Up to 48.2 months)

  2. Independent Review Facility (IRF)-Assessed DFS

    IRF-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an IRF-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. KM methodology was used to estimate the median DFS.

    Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)

  3. INV-assessed Disease-specific Survival (DSS)

    INV-assessed DSS was defined as the time from randomization to death from UC per investigator assessment of cause of death. Data for participants who did not die will be censored at the last date they were known to be alive. Data for participants who died from causes other than bladder cancer were censored at the date of death. KM methodology was used to estimate the median DSS.

    Time frame: From randomization to death from UC (Up to 48.2 months)

  4. INV-assessed Distant Metastasis-free Survival (DMFS)

    INV-assessed DMFS was defined as the time from randomization to the first occurrence of a DMFS event, defined as diagnosis of distant (i.e., non-locoregional) metastasis or death from any cause. Data for participants without a DMFS event were censored at the last date the participant was assessed to be alive and free of distant metastasis. Data for participants with no post-baseline disease assessment were censored at the randomization date. KM methodology was used to estimate the median DMFS.

    Time frame: From randomization to the first occurrence of a DMFS event (Up to 48.2 months)

  5. Time to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    TTCD of physical functioning (PF), role functioning (RF) \& health-related quality of life (HRQoL) was defined as time from randomization to first documented confirmed deterioration. Confirmed deterioration=participant's first ≥10-point score decrease from baseline on EORTC QLQ C30 PF, RF or GHS/QoL scale that must be held for ≤2 consecutive time points or followed by death due to cancer progression within 8 weeks from last patient-reported outcomes (PRO) assessment. EORTC QLQ-C30 has 30 questions assessing 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much) \& GHS/QoL on a 7-point scale (1=very poor to 7=excellent). Scores are linearly transformed on a scale of 0 to 100. High score=better functioning/better QoL.

    Time frame: Up to 11.8 months

  6. Percentage of Participants With ctDNA Clearance

    ctDNA clearance was defined as the percentage of participants who were ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1. Percentages have been rounded off.

    Time frame: Baseline, Day 1 of Cycles 3 or 5 (Cycle length = 28 days)

  7. Number of Participants With Adverse Events (AEs)

    AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From initiation of study treatment up to approximately 5 years

  8. Maximum Serum Concentration (Cmax) of Atezolizumab

    Time frame: 30 minutes post dose on Cycle 1 Day 1 (Cycle length = 28 days)

  9. Minimum Serum Concentration (Cmin) of Atezolizumab

    Time frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 8 and 12 (Cycle length = 28 days)

  10. Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

    Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to 12.8 months

07

Results

Posted Sep 28, 2026

Participant flow

A total of 761 participants with high-risk muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy were enrolled in the surveillance phase of the study after confirming no radiographic evidence of residual disease. Patients were eligible regardless of whether they had received prior platinum-based neoadjuvant chemotherapy (NAC). Participants were enrolled at 157 investigative sites across 24 countries. The study is still ongoing.

Surveillance Phase
Participant flow — Surveillance Phase
MilestoneSurveillance PhasePlaceboAtezolizumab
Started76100
Ctdna negative participants37700
Completed30700
Not completed45400
Withdrew: Ctdna negative participants - ongoing in surveillance phase800
Withdrew: Ctdna status unknown500
Withdrew: Ctdna positive screened for treatment phase37900
Withdrew: Withdrawal by subject2100
Withdrew: Investigator (inv)-assessed disease recurrence1900
Withdrew: Death1100
Withdrew: Protocol violation600
Withdrew: Physician decision400
Withdrew: Lost to follow-up100
Treatment Phase
Participant flow — Treatment Phase
MilestoneSurveillance PhasePlaceboAtezolizumab
Started083167
Safety-evaluable (se) population083165
Efficacy analysis population083167
Completed000
Not completed083167
Withdrew: Death03660
Withdrew: Withdrawal by subject087
Withdrew: Ongoing in study039100

Outcome measures

PrimaryINV-assessed Disease-free Survival (DFS)

INV-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an INV-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. Kaplan-Meier (KM) methodology was used to estimate the median DFS.

Time frame:
From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Reported as:
Median · months
INV-assessed Disease-free Survival (DFS)
monthsPlaceboAtezolizumab
INV-assessed Disease-free Survival (DFS)4.83 (4.07 to 8.34)9.86 (7.16 to 12.71)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.0047 · Hazard ratio (hr): 0.64 · 95% CI 0.47 to 0.87
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death from any cause. Data for participants who did not die at the time of analysis were censored at the date last known to be alive. Data for participants who did not have post-baseline information were censored at the date of randomization. KM methodology was used to estimate the median OS.

Time frame:
From randomization to death from any cause (Up to 48.2 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPlaceboAtezolizumab
Overall Survival (OS)21.13 (14.65 to NA)32.79 (27.66 to NA)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.0131 · Hazard ratio (hr): 0.59 · 95% CI 0.39 to 0.90
SecondaryIndependent Review Facility (IRF)-Assessed DFS

IRF-assessed DFS was defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Participants without an IRF-assessed DFS event were censored at the last date the participant was assessed to be alive and recurrence-free as determined with radiographic evidence. KM methodology was used to estimate the median DFS.

Time frame:
From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Reported as:
Median · months
Independent Review Facility (IRF)-Assessed DFS
monthsPlaceboAtezolizumab
Independent Review Facility (IRF)-Assessed DFS6.24 (4.11 to 8.34)9.30 (6.14 to 10.41)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.0101 · Hazard ratio (hr): 0.66 · 95% CI 0.48 to 0.91
SecondaryINV-assessed Disease-specific Survival (DSS)

INV-assessed DSS was defined as the time from randomization to death from UC per investigator assessment of cause of death. Data for participants who did not die will be censored at the last date they were known to be alive. Data for participants who died from causes other than bladder cancer were censored at the date of death. KM methodology was used to estimate the median DSS.

Time frame:
From randomization to death from UC (Up to 48.2 months)
Reported as:
Median · months
INV-assessed Disease-specific Survival (DSS)
monthsPlaceboAtezolizumab
INV-assessed Disease-specific Survival (DSS)NA (18.20 to NA)NA (32.79 to NA)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.0766 · Hazard ratio (hr): 0.64 · 95% CI 0.40 to 1.05
SecondaryINV-assessed Distant Metastasis-free Survival (DMFS)

INV-assessed DMFS was defined as the time from randomization to the first occurrence of a DMFS event, defined as diagnosis of distant (i.e., non-locoregional) metastasis or death from any cause. Data for participants without a DMFS event were censored at the last date the participant was assessed to be alive and free of distant metastasis. Data for participants with no post-baseline disease assessment were censored at the randomization date. KM methodology was used to estimate the median DMFS.

Time frame:
From randomization to the first occurrence of a DMFS event (Up to 48.2 months)
Reported as:
Median · months
INV-assessed Distant Metastasis-free Survival (DMFS)
monthsPlaceboAtezolizumab
INV-assessed Distant Metastasis-free Survival (DMFS)9.66 (6.51 to 13.27)14.09 (10.41 to 19.29)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.0198 · Hazard ratio (hr): 0.66 · 95% CI 0.47 to 0.94
SecondaryTime to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

TTCD of physical functioning (PF), role functioning (RF) \& health-related quality of life (HRQoL) was defined as time from randomization to first documented confirmed deterioration. Confirmed deterioration=participant's first ≥10-point score decrease from baseline on EORTC QLQ C30 PF, RF or GHS/QoL scale that must be held for ≤2 consecutive time points or followed by death due to cancer progression within 8 weeks from last patient-reported outcomes (PRO) assessment. EORTC QLQ-C30 has 30 questions assessing 5 aspects of participant functioning (physical, emotional, role, cognitive \& social), 3 symptom scales (fatigue, nausea \& vomiting \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much) \& GHS/QoL on a 7-point scale (1=very poor to 7=excellent). Scores are linearly transformed on a scale of 0 to 100. High score=better functioning/better QoL.

Time frame:
Up to 11.8 months
Reported as:
Median · months
Time to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
monthsPlaceboAtezolizumab
PFNA (19.35 to NA)25.13 (18.46 to NA)
RFNA (19.35 to NA)18.46 (12.22 to NA)
GHS/QoL16.49 (10.87 to NA)35.42 (19.25 to NA)
Statistical analysis
  • Placebo vs Atezolizumab · Log Rank · p = 0.3771 · Hazard ratio (hr): 1.25 · 95% CI 0.76 to 2.07
  • Placebo vs Atezolizumab · Log Rank · p = 0.1406 · Hazard ratio (hr): 1.45 · 95% CI 0.88 to 2.40
  • Placebo vs Atezolizumab · Log Rank · p = 0.1417 · Hazard ratio (hr): 0.71 · 95% CI 0.45 to 1.12
SecondaryPercentage of Participants With ctDNA Clearance

ctDNA clearance was defined as the percentage of participants who were ctDNA positive at baseline and ctDNA negative at Cycle 3, Day 1 or Cycle 5, Day 1. Percentages have been rounded off.

Time frame:
Baseline, Day 1 of Cycles 3 or 5 (Cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With ctDNA Clearance
percentage of participantsPlaceboAtezolizumab
Percentage of Participants With ctDNA Clearance14.5 (7.70 to 23.89)25.1 (18.77 to 32.44)
Statistical analysis
  • Placebo vs Atezolizumab · Cochran-Mantel-Haenszel · p = 0.0512 · Difference in ctdna clearance: 10.69 · 95% CI -0.24 to 21.62
SecondaryNumber of Participants With Adverse Events (AEs)

AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From initiation of study treatment up to approximately 5 years

Results for this outcome have not been posted.

SecondaryMaximum Serum Concentration (Cmax) of Atezolizumab
Time frame:
30 minutes post dose on Cycle 1 Day 1 (Cycle length = 28 days)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Maximum Serum Concentration (Cmax) of Atezolizumab
micrograms per milliliter (μg/mL)Atezolizumab
Maximum Serum Concentration (Cmax) of Atezolizumab500 ± 26.7
SecondaryMinimum Serum Concentration (Cmin) of Atezolizumab
Time frame:
Pre-dose on Day 1 of Cycles 2, 3, 4, 8 and 12 (Cycle length = 28 days)
Reported as:
Geometric mean · μg/mL
Minimum Serum Concentration (Cmin) of Atezolizumab
μg/mLAtezolizumab
Pre-dose on Cycle 2 Day 185.3 ± 40.9
Pre-dose on Cycle 3 Day 1114 ± 92.3
Pre-dose on Cycle 4 Day 1145 ± 43.2
Pre-dose on Cycle 8 Day 1184 ± 40.5
Pre-dose on Cycle 12 Day 1205 ± 49.8
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to 12.8 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab
ParticipantsAtezolizumab
Number of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab45

Adverse events

Collected over AEs and SAEs: From initiation of study treatment up to 14.7 months; All-Cause Mortality: Up to 48.2 months; Data collected up to the primary completion date is being reported here. Data collection is still ongoing, and final data will be reported one year after the study completion date. All-cause mortality: Efficacy analysis population (Treatment Phase). All enrolled participants (Surveillance Phase).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Surveillance Phase11/761 (1.4%)——
Placebo36/83 (43.4%)17/83 (20.5%)54/83 (65.1%)
Atezolizumab60/167 (35.9%)44/165 (26.7%)107/165 (64.8%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventSurveillance PhasePlaceboAtezolizumab
Urinary tract infectionInfections and infestations—4/8310/165
PyelonephritisInfections and infestations—0/834/165
IleusGastrointestinal disorders—2/833/165
HydronephrosisRenal and urinary disorders—2/830/165
Intestinal obstructionGastrointestinal disorders—0/833/165
Acute kidney injuryRenal and urinary disorders—0/833/165
Inguinal herniaGastrointestinal disorders—0/832/165
SepsisInfections and infestations—1/832/165
Renal failureRenal and urinary disorders—0/832/165
Arteriosclerosis coronary arteryCardiac disorders—1/830/165
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSurveillance PhasePlaceboAtezolizumab
PruritusSkin and subcutaneous tissue disorders—9/8329/165
Urinary tract infectionInfections and infestations—10/8325/165
AnaemiaBlood and lymphatic system disorders—3/8320/165
AstheniaGeneral disorders—10/8315/165
FatigueGeneral disorders—10/8318/165
ConstipationGastrointestinal disorders—6/8318/165
DiarrhoeaGastrointestinal disorders—9/8315/165
Blood creatinine increasedInvestigations—9/8313/165
HypothyroidismEndocrine disorders—1/8317/165
PyrexiaGeneral disorders—8/839/165

Baseline characteristics

Placebo and Atezolizumab arms: Efficacy analysis population included all participants randomized to receive study treatment regardless of the length of time between cystectomy and ctDNA positive status, when the primary analysis of DFS was conducted. Surveillance Participants: All participants other than those included in the efficacy analysis population.

Age, Categorical
Age, Categorical(Participants)Surveillance Participants (Not Randomized)PlaceboAtezolizumabTotal
<=18 years0000
Between 18 and 65 years1633550248
>=65 years34848117513
Sex: Female, Male
Sex: Female, Male(Participants)Surveillance Participants (Not Randomized)PlaceboAtezolizumabTotal
Female1241626166
Male38767141595
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Surveillance Participants (Not Randomized)PlaceboAtezolizumabTotal
Hispanic or Latino4591973
Not Hispanic or Latino43570141646
Unknown or Not Reported314742
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Surveillance Participants (Not Randomized)PlaceboAtezolizumabTotal
American Indian or Alaska Native70411
Asian1882752267
Native Hawaiian or Other Pacific Islander2002
Black or African American82010
White27650104430
More than one race2002
Unknown or Not Reported284739
08

Study locations

140 sites

Showing the first 100 of 140 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Urun Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE; IMvigor011 Investigators. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. 2025 Dec 18;393(24):2395-2408. doi: 10.1056/NEJMoa2511885. Epub 2025 Oct 20. PubMed 41124204 ↗
  • Jackson-Spence F, Toms C, O'Mahony LF, Choy J, Flanders L, Szabados B, Powles T. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 2023 Mar;19(7):509-515. doi: 10.2217/fon-2022-0868. Epub 2023 Apr 21. PubMed 37082935 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jun 2025, 49 months.

Results were first posted in Sep 2026, 1 year 3 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 49 months is close to that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 9, 2020
StartActual
May 3, 2021
Primary completionActual
Jun 15, 2025
CompletionActual
Oct 1, 2026
Results first posted
Sep 28, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Results
Results posted
posted Sep 28, 2026
Sites
2 sites added, 10 sites removed; no longer in Mexico
Show 2 added (1 Argentina, 1 Japan)
  • Instituto Alexander Fleming · Buenos Aires, Argentina
  • Tokushima University Hospital · Tokushima, Japan
Show 10 removed
  • Optum Health Care · Las Vegas, United States
  • Instituto Alexander Fleming · Buenos Aires, Argentina
  • Hospital Erasto Gaertner · Curitiba, Brazil
  • Chongqing Cancer Hospital · Chongqing, China
  • Azienda Ospedaliera Santa Maria di Terni · Terni, Italy
  • CUAN Hospital · San Pedro Garza García, Mexico
  • Ankara City Hospital · Ankara, Turkey (Türkiye)
  • Hospital Moinhos de Vento · Porto Alegre, Brazil
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola · Meldola, Italy
  • Hospital Universitario Virgen del Rocio · Seville, Spain
across 2 updates, Sep 28, 2026 – Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedInvestigatorINV-assessed (INV) - Disease-free Survival (DFS)Time frame: Randomization up to first occurrence of DFS event (up to approximately 49 months) → From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Sep 28, 2026
Documents
Secondary outcomes
8 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: Randomization up to death from any cause (up to approximately 6 years) → From randomization to death from any cause (Up to 48.2 months)
  • EditedIndependent Review Facility (IRF)-assessedAssessed DFSTime frame: Randomization up to first occurrence of DFS event (up to approximately 49 months) → From randomization to the first occurrence of a DFS event (Up to 48.2 months)
  • EditedINV-assessed Disease-specific Survival (DSS)Time frame: Randomization to death from UC (up to approximately 6 years) → From randomization to death from UC (Up to 48.2 months)
  • EditedINV-assessed Distant Metastasis-free Survival (DMFS)Time frame: Randomization to diagnosis of distant metastases or death from any cause (up to approximately 49 months) → From randomization to the first occurrence of a DMFS event (Up to 48.2 months)
  • EditedPercentage of Participants With ctDNA ClearanceTime frame: Baseline, Cycle 3 Day 1 or Cycle 5 Day 1 (each cycle is 28 days) → Baseline, Day 1 of Cycles 3 or 5 (Cycle length = 28 days)
  • EditedPercentageNumber of Participants With Adverse Events (AEs)Time frame: Baseline up to approximately 6 years → From initiation of study treatment up to approximately 5 years
  • EditedMaximum Serum Concentration (Cmax) of AtezolizumabTime frame: At pre-defined intervals from first administration of study drug (up to approximately 49 months) → 30 minutes post dose on Cycle 1 Day 1 (Cycle length = 28 days)
  • EditedIncidenceNumber of Participants With Anti-Drugdrug Antibodies (ADAs) to AtezolizumabTime frame: Baseline up to approximately 49 months → Up to 12.8 months
  • AddedTime to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)Time frame: Up to 11.8 months
  • AddedMinimum Serum Concentration (Cmin) of AtezolizumabTime frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 8 and 12 (Cycle length = 28 days)
  • RemovedTime to Confirmed Deterioration of Function and Health-related Quality of Life (HRQoL)Time frame: Randomization to participant's first score decrease of ≥ 10 points from baseline on EORTC QLQ-C30 physical function scale, role function scale, and the GHS/QoL Scale (up to approximately 49 months)
  • RemovedPrevalence of ADAs to AtezolizumabTime frame: Baseline
Sep 28, 2026
Show all 2 updates
  1. Nov 6, 2026
    Active, not recruiting→Completed
    2 sites added, 3 sites removed
    Show 2 added (1 Argentina, 1 Japan)
    • Instituto Alexander Fleming · Buenos Aires, Argentina
    • Tokushima University Hospital · Tokushima, Japan
    Show 3 removed
    • Hospital Moinhos de Vento · Porto Alegre, Brazil
    • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola · Meldola, Italy
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    + 2 other changes: verification date and date precision
  2. Sep 28, 2026
    Results posted
    7 sites removed; no longer in Mexico
    Show 7 removed
    • Optum Health Care · Las Vegas, United States
    • Instituto Alexander Fleming · Buenos Aires, Argentina
    • Hospital Erasto Gaertner · Curitiba, Brazil
    • Chongqing Cancer Hospital · Chongqing, China
    • Azienda Ospedaliera Santa Maria di Terni · Terni, Italy
    • CUAN Hospital · San Pedro Garza García, Mexico
    • Ankara City Hospital · Ankara, Turkey (Türkiye)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedInvestigatorINV-assessed (INV) - Disease-free Survival (DFS)Time frame: Randomization up to first occurrence of DFS event (up to approximately 49 months) → From randomization to the first occurrence of a DFS event (Up to 48.2 months)
    Secondary outcomes 8 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: Randomization up to death from any cause (up to approximately 6 years) → From randomization to death from any cause (Up to 48.2 months)
    • EditedIndependent Review Facility (IRF)-assessedAssessed DFSTime frame: Randomization up to first occurrence of DFS event (up to approximately 49 months) → From randomization to the first occurrence of a DFS event (Up to 48.2 months)
    • EditedINV-assessed Disease-specific Survival (DSS)Time frame: Randomization to death from UC (up to approximately 6 years) → From randomization to death from UC (Up to 48.2 months)
    • EditedINV-assessed Distant Metastasis-free Survival (DMFS)Time frame: Randomization to diagnosis of distant metastases or death from any cause (up to approximately 49 months) → From randomization to the first occurrence of a DMFS event (Up to 48.2 months)
    • EditedPercentage of Participants With ctDNA ClearanceTime frame: Baseline, Cycle 3 Day 1 or Cycle 5 Day 1 (each cycle is 28 days) → Baseline, Day 1 of Cycles 3 or 5 (Cycle length = 28 days)
    • EditedPercentageNumber of Participants With Adverse Events (AEs)Time frame: Baseline up to approximately 6 years → From initiation of study treatment up to approximately 5 years
    • EditedMaximum Serum Concentration (Cmax) of AtezolizumabTime frame: At pre-defined intervals from first administration of study drug (up to approximately 49 months) → 30 minutes post dose on Cycle 1 Day 1 (Cycle length = 28 days)
    • EditedIncidenceNumber of Participants With Anti-Drugdrug Antibodies (ADAs) to AtezolizumabTime frame: Baseline up to approximately 49 months → Up to 12.8 months
    • AddedTime to Confirmed Deterioration (TTCD) in Physical Functioning, Role Functioning & Global Health Status/Quality of Life (GHS/QoL), Assessed by European Organisation for Research & Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)Time frame: Up to 11.8 months
    • AddedMinimum Serum Concentration (Cmin) of AtezolizumabTime frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 8 and 12 (Cycle length = 28 days)
    • RemovedTime to Confirmed Deterioration of Function and Health-related Quality of Life (HRQoL)Time frame: Randomization to participant's first score decrease of ≥ 10 points from baseline on EORTC QLQ-C30 physical function scale, role function scale, and the GHS/QoL Scale (up to approximately 49 months)
    • RemovedPrevalence of ADAs to AtezolizumabTime frame: Baseline
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04660344
Lead sponsor
Hoffmann-La Roche
Collaborators
Natera, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
May 3, 2021
Primary completion
Jun 15, 2025
Completion
Oct 1, 2026
Results posted
Sep 28, 2026
Last update
Nov 6, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion